Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05476497 · ClinicalTrials.gov registry record · Phase 1
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
A Phase 1 study of Peanut Allergy, sponsored by Allergy Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 10
- Study locations
NCT05476497: Active Phase 1 study of Peanut Allergy, sponsored by Allergy Therapeutics.
NCT05476497 is a Phase 1 study of Peanut Allergy that is active but no longer recruiting, run by Allergy Therapeutics. The registered enrollment target is 46 participants, below the 211-participant average among 13 other Peanut Allergy trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05476497, a Phase 1 study of Peanut Allergy, is active but no longer recruiting, sponsored by Allergy Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 10
- Study locations
Study Summary
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL VLP Peanut
Study Locations (10)
Arizona
- University of Arizona - Tucson
Florida
- University of South Florida - Tampa
Kansas
- University of Kansas Medical Center - Kansas City
Massachusetts
- Massachusetts General Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Missouri
- Washington University School of Medicine - St Louis
New York
- Icahn School of Medicine at Mount Sinai - New York
Ohio
- Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2022-10-17 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT05476497 still lists
NCT05476497 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 211-participant average among 13 other Peanut Allergy trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Peanut Allergy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05476497 lists 10 locations in 10 states (Arizona, Florida, Kansas).
Frequently Asked Questions
What is clinical trial NCT05476497 about?
NCT05476497 is a clinical study titled "Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects". This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the deg...
What is the current status of trial NCT05476497?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2022-10-17. Estimated completion is 2026-11.
What conditions does trial NCT05476497 study?
This clinical trial studies the following conditions: Peanut Allergy.
What interventions are being tested in trial NCT05476497?
The interventions under investigation include: Placebo (BIOLOGICAL), VLP Peanut (BIOLOGICAL).
Who is sponsoring clinical trial NCT05476497?
This trial is sponsored by Allergy Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05476497 being conducted?
This trial has 10 study locations across Arizona, Florida, Kansas, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peanut Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05476497's enrollment target sits among peer trials
46 11th of 13 higher than 3 of 13 other Peanut Allergy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peanut Allergy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Peanut Sublingual Immunotherapy (SLIT)-Tablet for Treatment of Peanut Allergy
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
COMPLETED · Phase 1
-
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
COMPLETED · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI